Table 1. Pharmacokinetic parameters for belinostat after 30 min i.v. infusion in Phase I trial.
| Substance | Parameter* | 600 mg/m2 | 900 mg/m2 | 1200 mg/m2 | 1400 mg/m2 |
| Belinostat | No. of Patients | 3 | 3 | 6 | 5 |
| Cmax, µmol/L | 88.2±8.5 | 98.5±29.7 | 153.5±50.4 | 174.4±48.3 | |
| Tmax, h | 0.33±0.14 | 0.42±0.14 | 0.64±0.10 | 0.40±0.14 | |
| AUC0–24 h, h× µmol/L | 61.3±1.2 | 70.0±17.3 | 112.6±37.1 | 149.0±46.2 | |
| T1/2, h | 3.54±0.34 | 4.07±0.39 | 4.14±0.42 | 3.54±0.50 | |
| CL, L/h | 52.6±3.8 | 70.5±17.9 | 54.6±15.8 | 53.0±16.2 | |
| Vz, L | 268.3±26.6 | 409.2±76.7 | 304.9±185.6 | 279.1±120.8 | |
| Belinostat-G | AUC0–24 h, h× µmol/L | 286.5±36.6 | 302.1±54.8 | 514.1±41.4 | 575.1±154.0 |
| Relative Exposure | Bel-G/Bel AUC ratio | 4.79±0.46 | 4.22±0.15 | 4.82±1.80 | 4.13±0.68 |
Abbreviation: Cmax, maximum concentration; Tmax, time to maximum concentration; AUC0–24 h, area under the curve from 0 to 24 h; T1/2, half-life at the elimination phase; CL, clearance; Vz, volume of distribution. *Mean ± SD; AUC ratio was calculated based on AUC0–24 h of Bel-G (belinostat-G) over AUC0–24 h of Bel (belinostat).